Mr Gallahue has successfully participated in a variety of financial transactions, including initial public offerings, mergers, joint ventures, private placements and follow-on offerings at a number of healthcare companies, including Molecular Insight Pharmaceuticals, Keryx Biopharmaceuticals and LeukoSite.
Mr Sahagian will be responsible for production of the Valecor Platinum coronary stent, as well as manage the R&D of advanced surface modification technologies. Prior to joining CorNova, Mr Sahagian founded the medical device division at Implant Sciences. Mr Sahagian has earned his BS from the University of Lowell.
Eric Ryan, CEO of CorNova, said: “We needed to put in place the financial expertise required to move CorNova closer to becoming an advanced development and commercial organization. Bob’s depth of financial experience and knowledge of the biomedical industry will be a significant contribution to the growth and maturation of the company.”